Pfizer Prepares Third-Quarter Earnings Report Amid Lower Revenue Consensus

By EC Assets · Published 2 November 2026

Pfizer Inc. is scheduled to report third-quarter financial results before United States markets open on Tuesday, November 3, 2026. Wall Street approaches the announcement with a lower earnings bar and expectations for a softer operating quarter. Investors are seeking evidence that newer medicines in the company's portfolio can replace declining revenue from pandemic-era treatments. Consensus estimates place Pfizer's third-quarter revenue at 15 billion dollars. The performance update arrives as shareholders evaluate the company's capital returns and regular payouts. Pfizer currently carries an annual dividend yield of 5.64 percent, drawing focus from investors monitoring income distributions ahead of the release. Brokerage firms have recently adjusted their valuation targets for the New York Stock Exchange-listed drugmaker. Cantor Fitzgerald raised its price forecast for Pfizer shares to $27 from $24. The upward revision provided positive momentum for the equity, lifting shares during Tuesday trading. The company's wider capital structure includes historic debt financing transactions. Pfizer previously completed a $31 billion bond offering, which ranks among the largest corporate bond sales on record. When adjusted for inflation, that $31 billion issuance represents roughly half the size of Verizon's debt sale conducted in 2013. Pfizer's scheduled disclosure coincides with broader outperformance across healthcare investments. Biotechnology shares have beaten the wider equity market ahead of earnings announcements from major global pharmaceutical companies, with quarterly updates due from Pfizer, Novo Nordisk, and Moderna. Pfizer will release its third-quarter numbers before the opening bell on Tuesday, November 3, 2026. Moderna will publish its quarterly results on Friday. In clinical developments, the SITC conference will present new cancer-treatment findings from Immunocore and Candel. This article is intended for informational purposes only. It does not constitute investment advice.